Home » Pharma Blog Watch
Pharma Blog Watch
Sunesis
Targets CDKs (Xcovery Blog)
In response to an announcement this week by Sunesis Pharmaceuticals that it
has started a Phase I clinical trial of its cyclin-dependent kinase (CDK) inhibitor
in B-cell malignancies, Tim Gallagher writes, "The concern with targeting
CDKs is that they are so fundamental to cell function that any therapy needs
to be very, very well targeted, with above-average biological knowledge to compensate
for off-target effects."
"Not to mention the fact that as nuclear proteins, delivery for a-CDK compounds is much more complex than say targeting RTKs," he continues. "Perhaps success by Sunesis will increase interest in CDKs as targets."
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct